The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals

QJM: An International Journal of Medicine

Volumn 105, Issue 12, 2012, Pages 1179-1189

  Lachmann, P J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ARTICLE; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; LAW SUIT; LICENSING; LIMB DEFECT; PRESCRIPTION; PRIORITY JOURNAL; TERATOGENICITY;

EID: 84870328272     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs148     Document Type: Article

References (19)

1. Dally A. Thalidomide: was the tragedy preventable? The Lancet 1998; 351:1197-9.
2. Williams W. Wrongful ban on DDT costs lives. Eco Imperialism 2004; [http://www.eco-imperialism.com] Accessed October 2011.
3. Paumgartten FJ, Chahoud I. Thalidomide embryopathy cases in Brazil after 1965. Reprod Toxicol 2006; 22:1-2.
4. Cosyns JP. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 2003; 26:33-48.
5. The Boston Consulting Group. Life Sciences R&D: Changing the Innovation Equation in India. Cambridge, MA, US-India BioPharma & Healthcare Summit, 2011. [http://www.bcg.com/expertise_impact/biopharma_summit.aspx] Accessed October 2011.
6. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 22 January 2000.
7. Merton RK. The unanticipated consequences of purposive social action. Am Sociol Rev 1936; 1:894-904.
8. Directive 2006/25/EC of the European Parliament and of the Council of 5 Apr 2006 on the minimum health and safety requirements regarding the exposure of workers to risks arising from physical agents (artificial optical radiation) (19th individual Directive within the meaning of Article 16(1) of Directive 89/391/EEC). Official Journal of the European Union 27 April 2006.
9. Rose L. British health care regulation moves away from science. Biologist 2007; 54:3-5.
10. Scannell J, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Disc 2012; 11:191-200.
11. Bach PB. Limits on medicare's ability to control rising spending on cancer drugs. New Eng J Med 2009; 360:626-33.
12. Cooksey D. A Review of UK Health Research Funding. London, HMSO, 2006. [http://www.hm-treasury.gov.uk] Accessed October 2011.
13. Appeal Cases 562
14. Appeal Cases 85, at page 100
15. [2001] 3 All England Law Reports 289; [2001] Lloyd's Reports Medical 187; (2001) 60 Butterworths Medico-legal Reports 1
16. Cane P. Atiyah's Accidents, Compensation and the Law. 7th edn. Cambridge, UK, Cambridge University Press, 2006.
17. Jack A. AstraZeneca faces $ 520m Seroquel fine. Financial Times 2010; 28th April, Page 16.
18. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with Rosiglitazone or Pioglitazone. JAMA 2010; 304:411-8.
19. Clough AH. The Latest Decalogue. In: Mulhauser FL, ed. The Poems of Arthur Hugh Clough. 2nd edn. London, Oxford University Press, 1974.